{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T14:06:04Z","timestamp":1781359564759,"version":"3.54.1"},"reference-count":13,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Despite prophylaxis, acute graft-versus-host disease (aGVHD) occurs in up to 40% to 60% of patients undergoing an allogeneic hematopoietic stem cell transplantation (alloHSCT). Tacrolimus remains a common GVHD prophylactic medication used in combination with mycophenolate or methotrexate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The purpose of this study was to compare tacrolimus levels up to day +56 to clinical outcomes in patients who underwent alloHSCT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This was a retrospective cohort study of adult patients who underwent alloHSCT between January 2009 and April 2019 at Oregon Health and Science University (OHSU) Hospital. A logistic regression analysis was performed using SAS software to evaluate the association between tacrolimus concentration range and the GVHD grade outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>There were 295 patients included in the study. The median patient age was 53 years (range 18-72), the majority were males (55%), with a median comorbidity index of 2 (range 0-9). Most patients received peripheral blood stem cell transplant (95%). The median tacrolimus levels were divided into 4 groups: (1) between 3.8 and 4.9 ng\/mL, (2) 5.0 and 7.9 ng\/mL, (3) 8.0 and 9.9 ng\/mL, and (4) 10.0 and 10.7 ng\/mL in 8 (2.7%), 206 (69.8%), 71 (24.1%), and 10 (3.4%) of patients, respectively. The odds ratio of 0.193 (95% confidence interval [CI]: 0.045-0.836) suggested that patients in the tacrolimus 8 to 12 ng\/mL range were approximately 80.5% less likely to have grade 3 to 4 aGVHD compared to those in the 5 to 8 ng\/mL range.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and Relevance:<\/jats:title>\n                    <jats:p>Overall, we found that higher levels of tacrolimus (range 8-12 ng\/mL) in the first 8 weeks post-transplant were associated with improved outcomes without increased rate of relapse.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280251321324","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:47:17Z","timestamp":1740617237000},"page":"912-918","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Retrospective Analysis of Tacrolimus Levels: The First 56 Days Following Allogeneic Hematopoietic Stem Cell Transplant and Patient Outcomes"],"prefix":"10.1177","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2226-9747","authenticated-orcid":false,"given":"Kateryna","family":"Kovalenko","sequence":"first","affiliation":[{"name":"Moores Cancer Center, UC San Diego Health, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Bubalo","sequence":"additional","affiliation":[{"name":"Oregon Health &amp; Science University, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Saultz","sequence":"additional","affiliation":[{"name":"Oregon Health &amp; Science University, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavani","family":"Malla","sequence":"additional","affiliation":[{"name":"Oregon Health &amp; Science University, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.03.016"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.9.3634.bloodjournal8893634"},{"key":"e_1_3_2_4_2","unstructured":"Tacrolimus [package insert]. Mylan Pharmaceuticals Inc.; December 2023. Accessed June 10 2024. https:\/\/www.accessdata.fda.gov\/spl\/data\/a613c09f-71cb-465f-9033-7b0dd74b54e3\/a613c09f-71cb-465f-9033-7b0dd74b54e3.xml"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1053\/bbmt.1998.v4.pm9923414"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1053\/bbmt.1999.v5.pm10371361"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.323"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.07.029"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.09.001"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-2004"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.7212"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.06.008"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040613"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.113"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280251321324","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280251321324","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280251321324","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:14:02Z","timestamp":1777374842000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280251321324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":13,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1177\/10600280251321324"],"URL":"https:\/\/doi.org\/10.1177\/10600280251321324","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]}}}